Skip to content
value.today

Solid Biosciences Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to bookPrice to book of Pharmaceutical: $374 M to $1.5 B, median $725 M$0 M$403 M$806 M$1.2 B$1.6 BMarket value $713 M

Your own DCF model

A full discounted-cash-flow model of Solid Biosciences Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Pharmaceutical

Multiples of its companies with a market value at most 60 days old, times Solid Biosciences Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Solid Biosciences Inc.Applied toValue (25th to 75th)Companies
Price to book2.1× / 4.0× / 8.3×4.0×book equity $180 M$374 M to $1.5 B63

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Solid Biosciences Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

Price to book

4.0×

Now above its median of 2.9×, in the top quarter of its range; range 0.4× to 8.0× over 29 months.

0×2×4×6×8×2020202120222023202420252026Price to book 4×Median 3×

as of Oct 30, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 30, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025—$-174 M$-156 M$1 M$-157 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024—$-125 M$-100 M$1 M$-101 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023—$-96 M$-94 M$2 M$-96 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$8 M$-86 M$-98 M$3 M$-101 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$14 M$-72 M$-78 M$1 M$-79 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020—$-88 M$-57 M$1 M$-58 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $713 M on Oct 30, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.